An immune-educating therapy, Maveropepimut-S, elicits a diverse and active anti-tumor T cell response in patients with advanced recurrent ovarian cancer

maveropepimut-S (MVP-S) - IMV Inc

https://www.abstractsonline.com/pp8/#!/10828/presentation/3197

Kelcey Patterson; Barry Kennedy; Walead Ebrahimizadeh; Aurelio Lobo; Heather Hirsch; Heather Torrey; Valarmathy Kaliaperumal; Lisa MacDonald; Jeremy Graff; Stephan Fiset; Olga Hrytsenko

Mar 14, 2023